他克莫司治疗重症肌无力的临床疗效及细胞因子网络调节作用
Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis.
作者信息
Furukawa Yutaka, Yoshikawa Hiroaki, Iwasa Kazuo, Yamada Masahito
机构信息
Department of Neurology and Neurobiology of Aging, Kanazawa University, Kanazawa Japan.
出版信息
J Neuroimmunol. 2008 Mar;195(1-2):108-15. doi: 10.1016/j.jneuroim.2007.12.008. Epub 2008 Feb 11.
To clarify the long-term efficacy, safety and the cytokine network-modulating effects of tacrolimus in myasthenia gravis, medical records of 86 newly diagnosed consecutive patients and nine steroid-dependent patients were retrospectively reviewed, and peripheral blood mononuclear cells (PBMC) were cultured for the cytokine profile. Steroid reduction effects were observed by using tacrolimus, and no serious adverse effects were observed. The culture study showed reduced IL-12, IL-17, IFN-gamma, GM-CSF, TNF-alpha and MIP-1beta, and elevated IL-10 in the PBMC from patients who received tacrolimus, which suggests inhibition of T cells and macrophages, and enhancement of type 1 regulatory T cells.
为阐明他克莫司治疗重症肌无力的长期疗效、安全性及细胞因子网络调节作用，我们回顾性分析了86例新诊断的连续性患者及9例激素依赖患者的病历，并培养外周血单个核细胞（PBMC）以检测细胞因子谱。观察到使用他克莫司有激素减量效果，且未观察到严重不良反应。培养研究显示，接受他克莫司治疗患者的PBMC中白细胞介素-12（IL-12）、白细胞介素-17（IL-17）、γ干扰素（IFN-γ）、粒细胞-巨噬细胞集落刺激因子（GM-CSF）、肿瘤坏死因子-α（TNF-α）和巨噬细胞炎性蛋白-1β（MIP-1β）减少，而白细胞介素-10（IL-10）升高，这表明T细胞和巨噬细胞受到抑制，且1型调节性T细胞增强。
Zotero 插件